NYSE · ABT
Healthcare · Medical - Devices
$98.16
Up+$0.57 (+0.58%)
Updated Oct 7, 2026, 8:55 PM
SID Score
6.0/10
Composite research score
Smart Money
48/100
Neutral
Price performance · ABT
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
ABT closed at $98.16 after 21 trading sessions, down 6.97% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $100.56 | $100.95 | $97.94 | $98.16 | 10.58M |
| Oct 5, 2026 | $97.84 | $100.70 | $97.39 | $100.10 | 11.99M |
| Oct 2, 2026 | $97.25 | $97.59 | $95.06 | $97.50 | 8.71M |
| Oct 1, 2026 | $99.10 | $99.445 | $96.54 | $96.69 | 8.86M |
| Sep 30, 2026 | $100.57 | $100.63 | $98.72 | $98.83 | 7.57M |
| Sep 29, 2026 | $100.26 | $101.07 | $99.4805 | $100.95 | 8.05M |
| Sep 28, 2026 | $101.08 | $101.7619 | $100.255 | $100.98 | 6.8M |
| Sep 25, 2026 | $100.81 | $101.82 | $100.09 | $101.29 | 7.78M |
| Sep 24, 2026 | $103.77 | $104.22 | $101.02 | $101.07 | 6.22M |
| Sep 23, 2026 | $104.22 | $104.31 | $102.66 | $103.49 | 12.18M |
| Sep 22, 2026 | $104.01 | $104.54 | $102.895 | $103.69 | 8.38M |
| Sep 21, 2026 | $102.27 | $103.20 | $101.84 | $102.98 | 5.02M |
| Sep 18, 2026 | $101.83 | $103.19 | $101.50 | $102.61 | 27.08M |
| Sep 17, 2026 | $102.15 | $102.995 | $100.33 | $102.23 | 8.43M |
| Sep 16, 2026 | $101.89 | $103.30 | $101.50 | $102.36 | 5.23M |
| Sep 15, 2026 | $102.98 | $103.06 | $101.47 | $102.03 | 7.42M |
| Sep 14, 2026 | $103.56 | $104.44 | $102.57 | $103.09 | 7.79M |
| Sep 11, 2026 | $104.15 | $104.18 | $101.49 | $101.95 | 8.4M |
| Sep 10, 2026 | $105.18 | $105.19 | $103.18 | $103.36 | 7.85M |
| Sep 9, 2026 | $105.69 | $106.8599 | $104.78 | $105.23 | 6.47M |
| Sep 8, 2026 | $108.36 | $108.39 | $105.24 | $105.52 | 11.4M |
The latest Smart Investors Daily articles mentioning ABT.
Company
Market Activity
Research & News
ABT research
Company profile and research snapshot.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 2, 2026 | Rothschild & Co | Buy | — |
| Sep 8, 2026 | TD Cowen | Buy | — |
| Aug 25, 2026 | TD Cowen | Buy | — |
| Aug 13, 2026 | Wolfe Research | Outperform | — |
| Jul 28, 2026 | UBS | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 7, 2026
Muscle support just got simpler. Abbott (NYSE: ABT) today announced the launch of Ensure Max Protein 3-in-1 Muscle Support, a protein powder that combines three key ingredients in one product: protein to help build muscle tissue,† creatine to support exercise recovery‡* and HMB to help preserve muscle.
Benzinga · Oct 7, 2026
Analysts initiated coverage: Neutral on Honeywell Aerospace; Outperform on M&T Bank and SailPoint; Buy on Ambiq Micro; Overweight on Abbott.
Benzinga · Oct 7, 2026
Wall Street analysts revised targets: upgrades for NetApp and Humana; downgrades for PJT Partners; mixed target changes for Redwood, Marvell, Yum and S&P
Benzinga · Oct 7, 2026
Barclays analyst Matt Miksic initiates coverage on Abbott Laboratories (NYSE:ABT) with a Overweight rating and announces Price Target of $120.
Interpretive context generated from the platform’s current data sources.
Abbott Laboratories shares closed at $98.17, trading significantly below both key moving averages, with the 50-day moving average at $106.65 and the 200-day moving average at $102.47, per SID market data. The stock has declined 9.39% over the past month and 21.6% over the trailing twelve months, reflecting sustained downward pressure. ABT's 14-day relative strength index stands at 35.4, approaching oversold territory typically identified below 30. The stock carries a beta of 0.751, indicating lower volatility relative to the broader market, which is consistent with its defensive healthcare sector positioning. Average daily trading volume registers at approximately 8.88 million shares, according to Massive/Polygon data. Abbott's market capitalization currently stands at approximately $202.5 billion. The convergence of price below both major moving averages and the deteriorating RSI reading signals continued near-term technical weakness for the stock.
Abbott Laboratories trades at a price-to-earnings ratio of 31.15, a premium valuation relative to the broader healthcare sector, per SID market data. The stock's price-to-book ratio stands at 3.90, reflecting the market's pricing of Abbott's intangible assets and brand portfolio. Notably, the PEG ratio registers at negative 0.58, according to SEC filings, which suggests that consensus forward earnings growth estimates have turned negative, raising questions about the sustainability of the current earnings multiple. Abbott offers a dividend yield of 2.06%, providing income support for shareholders during the current period of price weakness. Within the healthcare sector, Abbott's premium P/E valuation historically reflects its diversified business model spanning diagnostics, medical devices, nutrition, and pharmaceuticals. However, the negative PEG ratio indicates that the current earnings multiple may face compression pressure if growth trends do not stabilize in upcoming quarters.
Abbott Laboratories registers a smart money score of 48 out of 100, reflecting a neutral overall signal, per SID market data. Institutional positioning scores a perfect 25 out of 25, indicating strong conviction from large asset managers and mutual funds, according to 13F institutional filings. In contrast, the insider activity score sits at just 9.3 out of 25, with 17 insider transactions recorded over the past 90 days — comprising 7 purchases and 10 sales, per SEC Form 4 filings. The net selling bias among corporate insiders suggests a cautious outlook from those with direct operational visibility. Dark pool activity scores 8.5 out of 25, indicating below-average institutional block trading interest at current price levels. Congressional trading activity registers at 5.1 out of 25, showing minimal engagement from elected officials. The divergence between strong institutional holdings and net insider selling creates a mixed signal, with institutional capital providing a floor while insider behavior leans modestly bearish.
Abbott Laboratories has delivered consecutive quarterly earnings beats in its two most recent reporting periods, according to company earnings reports. In the April 2026 quarter, Abbott posted earnings per share of $1.15 versus the $1.14 consensus estimate, a positive surprise of $0.01. The July 2026 quarter showed improvement, with actual EPS of $1.31 exceeding the $1.28 estimate by $0.03, per analyst estimates. Looking ahead, Wall Street consensus projects EPS of $1.42 for each of the next two reporting periods, scheduled for October 2026. The flat sequential estimate of $1.42 for both upcoming quarters suggests analysts anticipate earnings stabilization rather than meaningful acceleration. The modest beat pattern — ranging from less than 1% to approximately 2.3% — indicates Abbott is managing expectations conservatively. Investors will monitor whether the company can sustain its earnings beat streak while navigating current market headwinds impacting the healthcare sector.
Wall Street sentiment toward Abbott Laboratories has turned increasingly constructive in recent months, with multiple analyst upgrades recorded, per Wall Street analyst reports. On October 2, 2026, Rothschild & Co upgraded ABT from Neutral to Buy, the most recent positive rating change. Wolfe Research upgraded the stock from Peer Perform to Outperform on August 13, 2026, representing a notable shift in conviction. TD Cowen reiterated its Buy rating twice — on August 25 and September 8 — maintaining consistent bullish positioning, according to SID consensus data. UBS also maintained its Buy rating on July 28, 2026, reinforcing the prevailing positive consensus. The concentration of Buy and Outperform ratings across multiple firms, with zero downgrades during this period, suggests broad agreement among sell-side analysts that ABT's current price levels present value. The disconnect between analyst optimism and the stock's 21.6% trailing twelve-month decline indicates Wall Street expects a fundamental recovery ahead.
The latest Smart Investors Daily articles mentioning ABT.
